GT737
/ Grit Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 12, 2026
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Grit Biotechnology | Initiation date: Jul 2026 ➔ May 2027
Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33
July 01, 2026
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Grit Biotechnology
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33
1 to 2
Of
2
Go to page
1